Clinical Trials Browser

Phase 1 × Completed × pembrolizumab × Clear all

NCT02642809 2026-03-18

Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers

Phase 1 Completed

16 enrolled 13 charts

Gastrointestinal

Esophageal Neoplasms

NCT06108479 2026-03-18

Study of DF6215 in Patients With Advanced Solid Tumors

Phase 1 Completed

DermatologicGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1 Completed

83 enrolled 13 charts

Neuroendocrine Tumors

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06378047 2026-02-09

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02999477 2026-01-29

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Phase 1 Completed

32 enrolled 23 charts

Breast Neoplasms

NCT02856425 2026-01-20

PEMBIB

Phase 1 Completed

Other solid neoplasm

Patients With Any Advanced Solid Tumors

NCT02621398 2025-12-16

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Phase 1 Completed

23 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT05165433 2025-12-16

FORTIFY

Phase 1 Completed

Carcinoma, Neoplasm Metastasis

NCT03486301 2025-11-12

EIK1001

Phase 1 Completed

Neoplasms

NCT04840394 2025-11-12

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT04374877 2025-11-10

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Phase 1 Completed

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Neoplasms

NCT03010176 2025-10-29

MK-1454-001

Phase 1 Completed

156 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT04323202 2025-10-24

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

Phase 1 Completed

DermatologicHead & Neck

Basal Cell Carcinoma of the Head and Neck

NCT05082610 2025-10-16

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT02964013 2025-10-14

KEYVIBE-001

Phase 1 Completed

474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT05514444 2025-10-09

MK-4464-001

Phase 1 Completed

Neoplasms

NCT02586207 2025-10-07

Pembrolizumab in Combination With CRT for LA-SCCHN

Phase 1 Completed

59 enrolled 9 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Diseases, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Phase 1 Completed

Neoplasms

NCT03426891 2025-10-06

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Phase 1 Completed

21 enrolled 12 charts

Brain Neoplasms, Glioblastoma

NCT05501821 2025-09-25

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

Phase 1 Completed

Neoplasms

NCT04344795 2025-09-12

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Phase 1 Completed

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms

NCT05826275 2025-09-09

Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

Phase 1 Completed

HPV Associated Cancers

NCT02475213 2025-08-11

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Phase 1 Completed

146 enrolled 38 charts

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT05585034 2025-08-07

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Phase 1 Completed

260 enrolled 52 charts

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT02013154 2025-08-03

P102

Phase 1 Completed

Gastrointestinal

Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT02628574 2025-08-03

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Phase 1 Completed

Neoplasm Metastasis, Recurrence

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase 1 Completed

185 enrolled 28 charts

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04153565 2025-07-17

MK-3475-A17

Phase 1 Completed

19 enrolled 14 charts

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

NCT02680184 2025-07-04

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Phase 1 Completed

Melanoma

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase 1 Completed

56 enrolled 19 charts

GastrointestinalGenitourinaryLymphoidThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT05594043 2025-06-19

MK-6598-001

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03299088 2025-05-21

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

Phase 1 Completed

15 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT02318771 2025-05-15

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Phase 1 Completed

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

NCT03260322 2025-04-24

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT03954067 2025-04-22

A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors

Phase 1 Completed

Neoplasm Metastasis, Vaccinia

NCT04317066 2025-04-06

KEYNOTE-A33

Phase 1 Completed

7 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma, B-Cell

NCT04830592 2025-03-24

MOAT

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT03665597 2025-02-10

KEYNOTE-555

Phase 1 Completed

138 enrolled 34 charts 2 FDA

Melanoma

NCT03245489 2025-01-31

Anti-platelet + Pembro for H&N Tumors

Phase 1 Completed

Head and Neck Neoplasms

NCT03032107 2025-01-27

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

Phase 1 Completed

20 enrolled 14 charts

Breast Neoplasms

NCT05176509 2025-01-06

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT02630823 2025-01-03

MK-3475 Immunotherapy in Endometrial Carcinoma

Phase 1 Completed

10 enrolled 9 charts

Endometrial Neoplasms

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Phase 1 Completed

829 enrolled 100 charts

Neoplasms

NCT03092453 2024-12-24

Dendritic Cell Vaccination in Patients With Advanced Melanoma

Phase 1 Completed

5 enrolled 10 charts

Melanoma

NCT03922204 2024-12-11

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Phase 1 Completed

Lymphoma, B-Cell

NCT03846310 2024-12-09

ARC-4

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02794571 2024-12-05

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Phase 1 Completed

Neoplasm Metastasis